Mangoceuticals, Inc. (MGRX)

NCM – Real Time Price. Currency in USD

0.35

-0.07 (-17.84%)

At close: May 12, 2026, 4:00 PM EDT

0.38

+0.03 (9.99%)

Pre-market: May 13, 2026, 7:30 AM EDT

23.03.2026

Mangoceuticals Stock Doubles After Texas Lawsuit

Mangoceuticals Inc. (NASDAQ: MGRX) shares are surging on Monday. However, there is no news to justify the movement.

17.03.2026

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Dallas, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals,” the “Company,” or “MangoRx”), a company focused on developing, marketing, and selling health and wellness products through a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that it has filed a civil lawsuit against Clarity Ventures, Inc., its former technology consulting and software development firm (“Clarity”).

06.03.2026

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Dallas, TX, March 06, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions and its partner IntraMont Technologies, Inc. today announced the filing of a Patent Cooperation Treaty (PCT) international application (P-641039-PC) on February 26, 2026, to secure broad global patent protection for the antiviral animal feed and drinking water additive technology that powers MGX-0024.

23.02.2026

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

Dallas, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, today announced new data from its proprietary antiviral compound MGX-0024. A technical report issued by partner IntraMont Technologies in late 2025, combined with the final signed report from the ICAR-National Institute of High Security Animal Diseases (NIHSAD), Bhopal, supports MGX-0024's potential to reduce respiratory disease impacts in commercial poultry settings and provide meaningful early protection against highly pathogenic avian influenza (HPAI) H5N1 and other respiratory illnesses like Newcastle's disease, IBH, ILT, etc. in birds.

20.02.2026

Mangoceuticals Stock Skyrockets 50% Friday: What's Driving The Rally?

Here's what investors need to know.

20.02.2026

Mangoceuticals Stock Surges On Early Success Of Subscription TRT Model

Mangoceuticals, Inc. (NASDAQ: MGRX) shares are trading higher Friday after the company announced initial success for its newly launched all-inclusive injectable Testosterone Replacement Therapy treatment program.

19.02.2026

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

Month over Month Growth of 336% and 54% Reduction in Customer Acquisition Cost (CAC) DALLAS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company” or “MangoRx”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that MangoRx has experienced initial success for its newly launched all-inclusive injectable Testosterone Replacement Therapy (TRT) treatment program priced at $99 per month. The new TRT offer includes all doctor visits and medical consultations, lab work and analysis, and the medication to the extent prescribed.

Videos

No Data

There is no data to display

Press releases

17.03.2026

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

06.03.2026

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

23.02.2026

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

19.02.2026

Mangoceuticals, Inc. (MGRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Mangoceuticals, Inc. (MGRX)

Mangoceuticals Stock Doubles After Texas Lawsuit

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

Mangoceuticals Stock Skyrockets 50% Friday: What's Driving The Rally?

Mangoceuticals Stock Surges On Early Success Of Subscription TRT Model

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

Videos

No Data

Press releases

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

Mangoceuticals Stock Doubles After Texas Lawsuit

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

Mangoceuticals Stock Skyrockets 50% Friday: What's Driving The Rally?

Mangoceuticals Stock Surges On Early Success Of Subscription TRT Model

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

Videos

No Data

Press releases

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

Search stocks

Mangoceuticals, Inc. (MGRX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Mangoceuticals, Inc. (MGRX)

Mangoceuticals Stock Doubles After Texas Lawsuit

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

Mangoceuticals Stock Skyrockets 50% Friday: What's Driving The Rally?

Mangoceuticals Stock Surges On Early Success Of Subscription TRT Model

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

Videos

No Data

Press releases

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

Mangoceuticals Stock Doubles After Texas Lawsuit

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

Mangoceuticals Stock Skyrockets 50% Friday: What's Driving The Rally?

Mangoceuticals Stock Surges On Early Success Of Subscription TRT Model

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program

Videos

No Data

Press releases

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mangoceuticals' Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study

MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program